Core Viewpoint - Guichuang Tongqiao (02190) has announced a positive earnings forecast, expecting a significant increase in net profit and revenue for 2025, driven by strong sales of core products and accelerated international business growth [1] Financial Performance - The company anticipates a net profit exceeding RMB 240 million for 2025, representing a substantial year-on-year increase of approximately 139.4% [1] - Projected operating revenue is expected to surpass RMB 1.05 billion, reflecting a year-on-year growth of about 34.6% [1] Product Sales Growth - Sales revenue from key products such as the Tongqiao Qilin blood flow guiding device, neurovascular guide wire, UltraFree drug-eluting PTA balloon catheter, and ZYLOX Swan venous RF closure catheter have all experienced rapid growth [1] International Business Expansion - The company's international sales revenue has more than doubled year-on-year, with significant market penetration in key countries such as Germany, France, and Italy [1] - The internationalization strategy has achieved critical breakthroughs, leading to a comprehensive acceleration in overseas market expansion [1]
归创通桥盘中涨近7% 核心产品销售增长强劲 公司预计全年净利同比增近1.4倍